The case of SLE associated Sneddon-Wilkinson pustular disease successfully and safely treated with infliximab

1 Reed J  Wilkinson J  . Subcorneal pustular dermatosis. Clin Dermatol 2000; 18: 301–313.

2 Alexis AF  Strober BE  . Off-label dermatologic uses of anti-TNF-a therapies. J Cutan Med Surg 2005; 9: 296–302.

3 Hasan T  Nyberg F  Stephansson E  . Photosensitivity in lupus erythematosus, UV photoprovocation results compared with history of photosensitivity and clinical findings. Br J Dermatol 1997; 136: 699–705.

4 Grob JJ  Mege JL  Capo C  . Role of tumor necrosis factor-alpha in Sneddon-Wilkinson subcorneal pustular dermatosis. A model of neutrophil priming in vivo. J Am Acad Dermatol 1991; 25: 944–947.

5 Ramos-Casals M  Brito-Zeron P  Munoz S  . Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine 2007; 86: 242–251.

6 Aringer M  Steiner G  Graninger WB  Hofler E  Steiner CW  Smolen JS  . Effects of short term Infliximab therapy on autoantibodies in systemic lupus erythematosus. Arthritis Rheum 2007; 56: 274–279.

7 Bonifati C  Trento E  Cordiali Fei P  Muscardin L  Amantea A  Carducci M  . Early but not lasting improvement of recalcitrant subcorneal pustular dermatosis (Sneddon-Wilkinson disease) after infliximab therapy: relationships with variations in cytokine levels in suction blister fluids. Clin Exp Dermatol 2005; 30: 662–665.

8 Voigtlander C  Luftl M  Schuler G  Hertl M  . Infliximab (anti-tumor necrosis factor alpha antibody): a novel, highly effective treatment of recalcitrant subcorneal pustular dermatosis (Sneddon-Wilkinson disease). Arch Dermatol 2001; 137: 1571–1574.

9 Berk DR;  Hurt MA;  Mann C;  Sheinbein D;  . Sneddon-Wilkinson disease treated with etanercept: report of two cases. Clin Exp Dermato 2008; Aug 9. [Epub ahead of print, DOI: 10.1111/j.1365-2230.2008.02905.x]